ADVFN US – Market Content Editor

  • InspireMD tops Q4 estimates as revenue jumps, shares rise in premarket trading

    InspireMD tops Q4 estimates as revenue jumps, shares rise in premarket trading

    InspireMD Inc. (NASDAQ:NSPR) reported stronger-than-expected fourth-quarter results for 2025, beating both earnings and revenue forecasts as sales accelerated following the U.S. launch of its CGuard Prime device. The company posted earnings per share of -$0.14 for the quarter, outperforming analyst expectations of -$0.19. Revenue reached $3.15 million, well above the forecast of $2.32 million. Following…

  • Lifeward shares fall after Q4 results miss expectations

    Lifeward shares fall after Q4 results miss expectations

    Lifeward Ltd. (NASDAQ:LFWD) reported weaker-than-expected results for the fourth quarter of fiscal 2025, with both earnings and revenue coming in well below analyst forecasts. The disappointing performance sent the company’s shares down about 7% in premarket trading, with the stock changing hands near $7. The medical technology company reported earnings per share of -$2.85 for…

  • Akari Therapeutics to present ADC research at AACR Annual Meeting 2026

    Akari Therapeutics to present ADC research at AACR Annual Meeting 2026

    Akari Therapeutics Plc (NASDAQ:AKTX) said its research has been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, one of the leading global conferences for cancer research. The company’s abstract will be featured as a poster presentation during the event, which will take place April 17–22, 2026. The presentation will…

  • Artelo Biosciences moves into glaucoma research with fully funded clinical study

    Artelo Biosciences moves into glaucoma research with fully funded clinical study

    Artelo Biosciences (NASDAQ:ARTL) is expanding its development pipeline into ophthalmology with a new clinical study evaluating its drug candidate ART27.13 for the treatment of glaucoma. The San Diego–based clinical-stage biotech company said the investigator-sponsored trial will be fully funded through support from Glaucoma UK and the Health and Social Care (HSC) Research & Development Division,…

  • Ovid Therapeutics secures $60M funding to advance epilepsy drug programs

    Ovid Therapeutics secures $60M funding to advance epilepsy drug programs

    Ovid Therapeutics Inc. (NASDAQ:OVID) said Wednesday it has raised $60 million through a private placement to support the continued development of its epilepsy drug candidate OV329, including expanding research into seizures linked to tuberous sclerosis complex and infantile spasms. The biotechnology company, currently valued at about $262 million, has seen its shares climb roughly 337%…

  • Gran Tierra Energy shares slide after multiple board resignations

    Gran Tierra Energy shares slide after multiple board resignations

    Shares of Gran Tierra Energy Inc. (AMEX:GTE) dropped about 10% on Wednesday after the company disclosed that four members of its board had stepped down following disagreements tied to an audit committee investigation. According to a regulatory filing, Evan Hazell, Sondra Scott, David Smith and Brad Virbitsky resigned from the board on March 11 and…

  • Jabil tops Q2 estimates and lifts full-year forecast on strong data center demand

    Jabil tops Q2 estimates and lifts full-year forecast on strong data center demand

    Shares of Jabil Inc. (NYSE:JBL) rose about 1% in premarket trading on Wednesday after the electronics manufacturing services provider reported second-quarter results that exceeded analyst expectations and increased its outlook for the full fiscal year. For the second quarter of fiscal 2026, the company posted adjusted earnings of $2.69 per share, beating the consensus estimate…

  • Kanzhun shares decline after Q4 results announcement

    Kanzhun shares decline after Q4 results announcement

    Shares of Kanzhun (NASDAQ:BZ) fell about 4.4% after the company released its fourth-quarter financial results. The online recruitment platform reported adjusted earnings of $0.27 per ADS for the quarter, while revenue reached $297.2 million, marking a 14.0% increase from $260.8 million in the same period last year. The company said the performance was supported by…

  • Incannex says it holds $75 million in cash with zero debt after financing

    Incannex says it holds $75 million in cash with zero debt after financing

    Incannex Healthcare Inc. (NASDAQ:IXHL) said it currently holds about $75 million in cash and carries no debt following the completion of a recent financing round backed by healthcare-focused institutional investors, according to a company statement. At current trading levels, the clinical-stage biopharmaceutical company has a market capitalization of roughly $46 million, implying what the company…

  • CF Industries shares drop after Mizuho downgrades stock

    CF Industries shares drop after Mizuho downgrades stock

    Shares of CF Industries Holdings (NYSE:CF) fell about 3% on Wednesday morning after Mizuho lowered its rating on the fertilizer producer, warning that the stock’s recent rally may have gone too far. Mizuho analyst Edlain Rodriguez downgraded the shares to Underperform from Neutral and set a price target of $100, well below Tuesday’s closing price…